Most Biotechs have a fair run up in interest when they enter Phase 3 trials and if successful have a big jump in price. A further jump in price comes with FDA approval.
Cellucreme is only going to have one announcement. If it works it is straight to market.
That means Phase 2 and Phase 3 and FDA Approval risks are removed.
This just needs Pre-Clinical success and we are off to market.
Jevalent has done some great numbers on what could be acheived here. Jev could you repost your analysis for discussion.
PoS
Most Biotechs have a fair run up in interest when they enter...
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(33.3%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.2¢ | $2.565K | 874.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 40547400 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 39021116 | 27 |
View Market Depth
| Last trade - 15.59pm 12/11/2024 (20 minute delay) ? |
| AVE (ASX) Chart |